arznei-telegramm® 12/2016 |
THERAPY FROM A CRITICAL VIEWPOINT |
Celecoxib (CELEBREX, generics) - as safe as naproxen and ibuprofen regarding cardiovascular events? |
Prevention of thromboembolism after knee arthroscopy or lower-leg casting |
Rivaroxaban for patients with atrial fibrillation undergoing placement of stents: doubtful benefits compared with warfarin |
a-t READERS QUESTIONS AND COMMENTS | Adjuvanted flu vaccine FLUAD … clinical efficacy benefits still not proven |
Carotis plaques detected by screening in healthy people - what should you do? |
Restrict package size for colchicine preparations |
IN BRIEF |
USA: warning notice for homoeopathics |
Pfizer/UK: 100 million € fine because of high prices |
CURRENT ADR NETWORK REPORT |
Angioedema and other intolerance reactions with oral lavendula oil (LASEA) |
SIDE EFFECTS |
Unusual coloured urine due to drugs |
e a-t ON THE INTERNET |
Hepatitis C: sofosbuvir plus velpatasvir (EPCLUSA |